Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-05-10
2011-05-10
Harris, Alana M (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S135100, C424S136100, C424S138100, C424S144100, C424S152100, C424S154100, C424S155100, C424S156100, C424S174100, C424S178100, C424S181100, C424S183100, C530S350000, C530S386000, C530S387100, C530S387300, C530S388100, C530S388150, C530S388200
Reexamination Certificate
active
07939073
ABSTRACT:
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5698178 (1997-12-01), Goldenberg
patent: 5789554 (1998-08-01), Leung et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 7018809 (2006-03-01), Carter
patent: 510 949 (1992-04-01), None
patent: WO 90/09196 (1990-08-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 96/04925 (1996-02-01), None
patent: WO 98/42378 (1998-01-01), None
patent: WO 99/02567 (1999-01-01), None
Blair and Ghose. Linkage of Cytotoxic Agents to Immunoglobulins. Journal of Immunological Methods 59: 129-143, 1983.
Hashida et al. More Useful Maleimide Compounds for the Conjugation of Fab' to Horseradish Peroxidase through Thiol Groups in the Hinge. Journal of Applied Biochemistry 6: 56-63, 1984.
Li et al. The Epitope specificity and tissue reactivity of four murine monoclonal anti-cd22 antibodies. Cellular Immunology 118: 85-99, 1989.
S. Kiesel et al. “Removal of Cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement . . . ”, Leukemia Research vol. II, No. 12, 1987, pp. 1119-1125.
O. Press, “Prospects for the management on non-Hodgkin's lymphomas with monoclonal antibodies and Immunoconjugates.” Cancer Journal from Scientific American, vol. 4, No. suppl. 2, Jul. 1998.
D. Maloney et al. “Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal Antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma” Blood, vol. 84, No. 8, 1994.
M. Ghetie et al. “A Combination of immunotoxins and chemotherapy can cure SCID mice of Human B-Cell Tumors” The Faseb Journal, vol. 8, No. 4, 1994.
D. Flavell et al., “Systematic Therapy with 3BIT, a triple combination cocktail of anti-CD19,-CD22, and-CD38 Saporin Immunotoxin, is curative of human B-Cell . . . ” Cancer Research, vol. 57, No. 21, 1997.
Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with hum Ig heavy and light Chain YACS”, Nature Genetic, vol. 7, pp. 13-21 , 1994.
R. French et al., “Response of B-cell lymphomato a combination of bispecific antibodies and saporin” Leukemia Research, vol. 20, No. 7, Jul. 1996.
C. Renner et al. “Monoclonal antibodies in the treatment of non-Hodgkin's Lymphoma: recent results and Future Prospects” Leukemia, vol. 11, No. suppl. 2, Apr. 1997.
J. Leonard et. “Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results” Blood, vol. 94, No. 10 suppl. 1 part 1, 1999.
Kaminski et al., “Radioimmunotheraphy of B-Cell lymphoma with (131) Anti-B1 [Anti-CD20] Antibody”, New England J. of Medicine 329(7): 459-465, Aug. 12, 1993.
Vuist et al., “Potentiation by interleukin 2 of burkitt's lymphoma therapy with Anti-Pan B (Anti-CD19) monoclonal antibodies in a mouse xenotransplantation model”, Cancer Research, vol. 53, pp. 819-825, 1989.
Juweid et al., “Treatment of non-hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22”, Cancer Research (Suppl.) vol. 55, pp. 5899s-5907s, Dec. 1, 1995.
Harris Alana M
Immunomedics Inc.
Rossi Kimms & McDowell LLP
LandOfFree
Immunotherapy of B-cell malignancies using anti-CD22 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy of B-cell malignancies using anti-CD22 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of B-cell malignancies using anti-CD22 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688142